Find information on thousands of medical conditions and prescription drugs.

Sulfamethoxazole

Sulfamethoxazole is a sulfonamide antibiotic. It is most often used as part of a synergistic combination with trimethoprim in a 5:1 ratio in co-trimoxazole, which is also known as Bactrim or Septrim. It can be used an alternative of amoxicillin-based antibiotics to treat sinusitis.

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
Growth hormone
Salbutamol
Salmeterol
Sandimmune
Sandostatin
Sansert
Saquinavir
Sarafem
Satric
Scopolamine
Seasonale
Secobarbital
Secretin
Selegiline
Semprex-D
Sensipar
Sensorcaine
Serax
Serevent
Serine
Seroquel
Serostim
Serrapeptase
Sertindole
Sertraline
Serzone
Sevelamer
Sevoflurane
Sibutramine
Sildenafil
Silibinin
Simvastatin
Sinemet
Sinequan
Singulair
Sirolimus
Skelaxin
Sodium cyclamate
Solage
Soma
Somatostatin
Sotahexal
Sotalol
Sotret
Spiperone
Spiriva
Spironolactone
Sporahexal
Sporanox
SPS
SSD
Stanozolol
Stavudine
Stelazine
Stilbestrol
Stilbetin
Stimate
Stiripentol
Strattera
Streptokinase
Streptomycin
Suboxone
Subutex
Sucralfate
Sucralfate
Sufentanil
Sulbactam
Sulfamethoxazole
Sulfanilamide
Sulfasalazine
Sulforidazine
Sulla
Sulpiride
Sultamicillin
Sumatriptan
Suprefact
Suramin sodium
Sustaire
Sustiva
Suxamethonium chloride
Symmetrel
Synarel
Synercid
Synthroid
Syntocinon
Zaleplon
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Increased Resistance to One Drug Used in HIV Patients. - trimethoprim-sulfamethoxazole TMP-SMX
From American Family Physician, 4/15/00 by Karl E. Miller

One of the most effective agents used for preventing pneumocystic infections in patients with human immunodeficiency virus (HIV) infection is trimethoprim-sulfamethoxazole (TMP-SMX). However, long-term use of this antibiotic may increase the risk for creating resistant organisms. If the risk for developing resistant organisms is high, an alternative treatment strategy may be necessary. Martin and associates studied the impact of TMP-SMX on the incidence of resistant organisms before and during the widespread use of this antibiotic in HIV patients.

The study consisted of evaluating the incidence of resistance to TMP-SMX in patients at a general hospital. From 1988 through 1995, each culture sample that was submitted to the clinical microbiology laboratory was recorded. For each sample, the date and site of collection, demographic information, and microbiologic and antimicrobial susceptibility data were noted. All inpatients and outpatients who were infected with Staphylococcus aureus or one of seven Enterobacteriaceae species and who had TMP-SMX susceptibility testing were included in the study.

Resistance of all isolates to TMP-SMX increased from less than 5.5 percent before 1988 to 20.4 percent in 1995. HIV-infected patients had a significantly higher incidence of resistance than the general population. The largest increase was in Escherichia coli and S. aureus in patients with HIV. During the same period, a rapid rise in TMP-SMX use occurred in relation to pneumocystic infection prevention.

The authors conclude that in an area with a high incidence of HIV infection, the use of TMP-SMX for empiric pneumocystic infection prevention should no longer be an option. Because of the increase of resistant organisms, the use of this broad-spectrum antibiotic in HIV patients may select for multiresistant organisms and complicate future therapeutic options.

KARL E. MILLER, M.D.

Martin JN, et al. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. J Infect Dis December 1999;180:1809-18.

COPYRIGHT 2000 American Academy of Family Physicians
COPYRIGHT 2000 Gale Group

Return to Sulfamethoxazole
Home Contact Resources Exchange Links ebay